Dragging ras back in the ring

Cancer Cell

Volumn 25, Issue 3, 2014, Pages 272-281

  Stephen, Andrew G ^a   Esposito, Dominic ^a   Bagni, Rachelc G ^a   McCormick, Frank ^a,b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE EXCHANGE FACTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; RAF PROTEIN; RAP PROTEIN; RAS PROTEIN; GUANOSINE TRIPHOSPHATE; ISOPROTEIN; ONCOPROTEIN;

ALLELE; CODON USAGE; COLON CANCER; ENDOMETRIUM CANCER; FEEDBACK SYSTEM; GENE EXPRESSION; GENE MUTATION; HEPATOBILIARY SYSTEM CANCER; HUMAN; LUNG ADENOCARCINOMA; NEUROBLASTOMA; ONCOGENE K RAS; ONCOGENE RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; RHABDOMYOSARCOMA; SKIN CANCER; SMALL INTESTINE CANCER; TUMOR GENE; URINARY TRACT CANCER; UTERINE CERVIX CANCER; DRUG TARGETING; ELECTROPHILICITY; HYDROLYSIS; LUNG CANCER; MELANOMA; NEOPLASM; ONCOGENE; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HUMANS; MICE; NEOPLASMS; ONCOGENE PROTEIN P21(RAS); PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS P21(RAS); RETROVIRIDAE INFECTIONS; SIGNAL TRANSDUCTION; TUMOR VIRUS INFECTIONS;

EID: 84896090174     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.02.017     Document Type: Review

References (86)

1. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., De Greve J., Douillard J.Y., Lathia C., Schwartz B., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J.Clin. Oncol. 2006, 24:4293-4300.
2. Ahmadian M.R., Zor T., Vogt D., Kabsch W., Selinger Z., Wittinghofer A., Scheffzek K. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc. Natl. Acad. Sci. USA 1999, 96:7065-7070.
3. Barbacid M. ras genes. Annu. Rev. Biochem. 1987, 56:779-827.
4. Bivona T.G., Quatela S.E., Bodemann B.O., Ahearn I.M., Soskis M.J., Mor A., Miura J., Wiener H.H., Wright L., Saba S.G., et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 2006, 21:481-493.
5. Blasco R.B., Francoz S., Santamaría D., Cañamero M., Dubus P., Charron J., Baccarini M., Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011, 19:652-663.
6. Bos J.L., Rehmann H., Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007, 129:865-877.
7. Brems H., Chmara M., Sahbatou M., Denayer E., Taniguchi K., Kato R., Somers R., Messiaen L., De Schepper S., Fryns J.P., et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat. Genet. 2007, 39:1120-1126.
8. Buhrman G., Holzapfel G., Fetics S., Mattos C. Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc. Natl. Acad. Sci. USA 2010, 107:4931-4936.
9. Chan G., Gu S., Neel B.G. Erk1 and Erk2 are required for maintenance of hematopoietic stem cells and adult hematopoiesis. Blood 2013, 121:3594-3598.
10. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
11. Clark R., Wong G., Arnheim N., Nitecki D., McCormick F. Antibodies specific for amino acid 12 of the ras oncogene product inhibit GTP binding. Proc. Natl. Acad. Sci. USA 1985, 82:5280-5284.
12. Corcoran R.B., Ebi H., Turke A.B., Coffee E.M., Nishino M., Cogdill A.P., Brown R.D., Della Pelle P., Dias-Santagata D., Hung K.E., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
13. Court H., Amoyel M., Hackman M., Lee K.E., Xu R., Miller G., Bar-Sagi D., Bach E.A., Bergö M.O., Philips M.R. Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. J.Clin. Invest. 2013, 123:4681-4694.
14. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
15. Der C.J., Krontiris T.G., Cooper G.M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl. Acad. Sci. USA 1982, 79:3637-3640.
16. De Roock W., Jonker D.J., Di Nicolantonio F., Sartore-Bianchi A., Tu D., Siena S., Lamba S., Arena S., Frattini M., Piessevaux H., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
17. Eckhart W., Hutchinson M.A., Hunter T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell 1979, 18:925-933.
18. Feng Z., Hu W., Chen J.X., Pao A., Li H., Rom W., Hung M.C., Tang M.S. Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J.Natl. Cancer Inst. 2002, 94:1527-1536.
19. Feramisco J.R., Clark R., Wong G., Arnheim N., Milley R., McCormick F. Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature 1985, 314:639-642.
20. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001, 15:3249-3262.
21. Geyer M., Schweins T., Herrmann C., Prisner T., Wittinghofer A., Kalbitzer H.R. Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Biochemistry 1996, 35:10308-10320.
22. Giroux S., Tremblay M., Bernard D., Cardin-Girard J.F., Aubry S., Larouche L., Rousseau S., Huot J., Landry J., Jeannotte L., Charron J. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 1999, 9:369-372.
23. González-García A., Pritchard C.A., Paterson H.F., Mavria G., Stamp G., Marshall C.J. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 2005, 7:219-226.
24. Gysin S., Salt M., Young A., McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2:359-372.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
26. Hatano N., Mori Y., Oh-hora M., Kosugi A., Fujikawa T., Nakai N., Niwa H., Miyazaki J., Hamaoka T., Ogata M. Essential role for ERK2 mitogen-activated protein kinase in placental development. Genes Cells 2003, 8:847-856.
27. Holderfield M., Merritt H., Chan J., Wallroth M., Tandeske L., Zhai H., Tellew J., Hardy S., Hekmat-Nejad M., Stuart D.D., et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 2013, 23:594-602.
28. Huang Y., Rangwala F., Fulkerson P.C., Ling B., Reed E., Cox A.D., Kamholz J., Ratner N. Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells. Oncogene 2004, 23:368-378.
29. Ihle N.T., Byers L.A., Kim E.S., Saintigny P., Lee J.J., Blumenschein G.R., Tsao A., Liu S., Larsen J.E., Wang J., et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J.Natl. Cancer Inst. 2012, 104:228-239.
30. Johnson L., Greenbaum D., Cichowski K., Mercer K., Murphy E., Schmitt E., Bronson R.T., Umanoff H., Edelmann W., Kucherlapati R., Jacks T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 1997, 11:2468-2481.
31. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9:517-531.
32. Kashatus D.F. Ral GTPases in tumorigenesis: emerging from the shadows. Exp. Cell Res. 2013, 319:2337-2342.
33. Kumar M.S., Hancock D.C., Molina-Arcas M., Steckel M., East P., Diefenbacher M., Armenteros-Monterroso E., Lassailly F., Matthews N., Nye E., et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012, 149:642-655.
34. Kung H.F., Smith M.R., Bekesi E., Manne V., Stacey D.W. Reversal of transformed phenotype by monoclonal antibodies against Ha-ras p21 proteins. Exp. Cell Res. 1986, 162:363-371.
35. Lampson B.L., Pershing N.L., Prinz J.A., Lacsina J.R., Marzluff W.F., Nicchitta C.V., MacAlpine D.M., Counter C.M. Rare codons regulate KRas oncogenesis. Curr. Biol. 2013, 23:70-75.
36. Liao J., Shima F., Araki M., Ye M., Muraoka S., Sugimoto T., Kawamura M., Yamamoto N., Tamura A., Kataoka T. Two conformational states of Ras GTPase exhibit differential GTP-binding kinetics. Biochem. Biophys. Res. Commun. 2008, 369:327-332.
37. Lim K.H., Ancrile B.B., Kashatus D.F., Counter C.M. Tumour maintenance is mediated by eNOS. Nature 2008, 452:646-649.
38. Lim S.M., Westover K.D., Ficarro S.B., Harrison R.A., Choi H.G., Pacold M.E., Carrasco M., Hunter J., Kim N.D., Xie T., et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew. Chem. Int. Ed. Engl. 2014, 53:199-204.
39. Lito P., Rosen N., Solit D.B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 2013, 19:1401-1409.
40. Lopez-Alcalá C., Alvarez-Moya B., Villalonga P., Calvo M., Bachs O., Agell N. Identification of essential interacting elements in K-Ras/calmodulin binding and its role in K-Ras localization. J.Biol. Chem. 2008, 283:10621-10631.
41. Macdonald S.G., Crews C.M., Wu L., Driller J., Clark R., Erikson R.L., McCormick F. Reconstitution of the Raf-1-MEK-ERK signal transduction pathway invitro. Mol. Cell. Biol. 1993, 13:6615-6620.
42. Marte B.M., Rodriguez-Viciana P., Wennstrom S., Warne P.H., Downward J. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr. Biol. 1997, 7:63-70.
43. Martin T.D., Samuel J.C., Routh E.D., Der C.J., Yeh J.J. Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res. 2011, 71:206-215.
44. Maurer T., Garrenton L.S., Oh A., Pitts K., Anderson D.J., Skelton N.J., Fauber B.P., Pan B., Malek S., Stokoe D., et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 2012, 109:5299-5304.
45. Mirzoeva O.K., Das D., Heiser L.M., Bhattacharya S., Siwak D., Gendelman R., Bayani N., Wang N.J., Neve R.M., Guan Y., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009, 69:565-572.
46. Montero-Conde C., Ruiz-Llorente S., Dominguez J.M., Knauf J.A., Viale A., Sherman E.J., Ryder M., Ghossein R.A., Rosen N., Fagin J.A. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3:520-533.
47. Moodie S.A., Willumsen B.M., Weber M.J., Wolfman A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993, 260:1658-1661.
48. Neel N.F., Martin T.D., Stratford J.K., Zand T.P., Reiner D.J., Der C.J. The RalGEF-Ral effector signaling network: the road less traveled for anti-Ras drug discovery. Genes Cancer 2011, 2:275-287.
49. Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
50. Parada L.F., Tabin C.J., Shih C., Weinberg R.A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982, 297:474-478.
51. Potenza N., Vecchione C., Notte A., De Rienzo A., Rosica A., Bauer L., Affuso A., De Felice M., Russo T., Poulet R., et al. Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep. 2005, 6:432-437.
52. Prior I.A., Lewis P.D., Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012, 72:2457-2467.
53. Puyol M., Martín A., Dubus P., Mulero F., Pizcueta P., Khan G., Guerra C., Santamaría D., Barbacid M. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
54. Quinlan M.P., Settleman J. Isoform-specific ras functions in development and cancer. Future Oncol. 2009, 5:105-116.
55. Rauen K.A. The RASopathies. Annu. Rev. Genomics Hum. Genet. 2013, 14:355-369.
56. Rodriguez-Viciana P., Sabatier C., McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 2004, 24:4943-4954.
57. Saba-El-Leil M.K., Vella F.D., Vernay B., Voisin L., Chen L., Labrecque N., Ang S.L., Meloche S. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep. 2003, 4:964-968.
58. Santos E., Tronick S.R., Aaronson S.A., Pulciani S., Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 1982, 298:343-347.
59. Sasaki A.T., Carracedo A., Locasale J.W., Anastasiou D., Takeuchi K., Kahoud E.R., Haviv S., Asara J.M., Pandolfi P.P., Cantley L.C. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci. Signal. 2011, 4:ra13.
60. Scholl F.A., Dumesic P.A., Barragan D.I., Harada K., Bissonauth V., Charron J., Khavari P.A. Mek1/2 MAPK kinases are essential for mammalian development, homeostasis, and Raf-induced hyperplasia. Dev. Cell 2007, 12:615-629.
61. Schubbert S., Bollag G., Lyubynska N., Nguyen H., Kratz C.P., Zenker M., Niemeyer C.M., Molven A., Shannon K. Biochemical and functional characterization of germ line KRAS mutations. Mol. Cell. Biol. 2007, 27:7765-7770.
62. Shih T.Y., Weeks M.O., Young H.A., Scolnick E.M. p21 of Kirsten murine sarcoma virus is thermolabile in a viral mutant temperature sensitive for the maintenance of transformation. J.Virol. 1979, 31:546.
63. Shirouzu M., Koide H., Fujita-Yoshigaki J., Oshio H., Toyama Y., Yamasaki K., Fuhrman S.A., Villafranca E., Kaziro Y., Yokoyama S. Mutations that abolish the ability of Ha-Ras to associate with Raf-1. Oncogene 1994, 9:2153-2157.
64. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
65. Sobczak I., Galabova-Kovacs G., Sadzak I., Kren A., Christofori G., Baccarini M. B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis. Oncogene 2008, 27:4779-4787.
66. Stokoe D., McCormick F. Activation of c-Raf-1 by Ras and Src through different mechanisms: activation invivo and invitro. EMBO J. 1997, 16:2384-2396.
67. Stowe I.B., Mercado E.L., Stowe T.R., Bell E.L., Oses-Prieto J.A., Hernández H., Burlingame A.L., McCormick F. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 2012, 26:1421-1426.
68. Sun Q., Burke J.P., Phan J., Burns M.C., Olejniczak E.T., Waterson A.G., Lee T., Rossanese O.W., Fesik S.W. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 2012, 51:6140-6143.
69. Taparowsky E., Suard Y., Fasano O., Shimizu K., Goldfarb M., Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 1982, 300:762-765.
70. To M.D., Wong C.E., Karnezis A.N., Del Rosario R., Di Lauro R., Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat. Genet. 2008, 40:1240-1244.
71. Trahey M., McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 1987, 238:542-545.
72. Turke A.B., Song Y., Costa C., Cook R., Arteaga C.L., Asara J.M., Engelman J.A. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012, 72:3228-3237.
73. Van Aelst L., Barr M., Marcus S., Polverino A., Wigler M. Complex formation between RAS and RAF and other protein kinases. Proc. Natl. Acad. Sci. USA 1993, 90:6213-6217.
74. Villalonga P., López-Alcalá C., Bosch M., Chiloeches A., Rocamora N., Gil J., Marais R., Marshall C.J., Bachs O., Agell N. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol. Cell. Biol. 2001, 21:7345-7354.
75. Vogt P.K. Retroviral oncogenes: a historical primer. Nat. Rev. Cancer 2012, 12:639-648.
76. Wahlstrom A.M., Cutts B.A., Karlsson C., Andersson K.M., Liu M., Sjogren A.K., Swolin B., Young S.G., Bergo M.O. Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease. Blood 2007, 109:763-768.
77. Warne P.H., Viciana P.R., Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 invitro. Nature 1993, 364:352-355.
78. Weiwer M., Spoonamore J., Wei J., Guichard B., Ross N.T., Masson K., Silkworth W., Dandapani S., Palmer M., Scherer C.A., et al. A potent and selective quinoxalinone-based STK33 inhibitor does not show synthetic lethality in KRAS-dependent cells. ACS Med. Chem. Lett. 2012, 3:1034-1038.
79. Wu X., Upadhyaya P., Villalona-Calero M.A., Briesewitz R., Pei D. Inhibition of Ras-effector interaction by cyclic peptides. Medchemcomm 2013, 4:378-382.
80. Xu J., Hedberg C., Dekker F.J., Li Q., Haigis K.M., Hwang E., Waldmann H., Shannon K. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood 2012, 119:1032-1035.
81. Yang M.H., Laurent G., Bause A.S., Spang R., German N., Haigis M.C., Haigis K.M. HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol. Cancer Res. 2013, 11:1072-1077.
82. Yao Y., Li W., Wu J., Germann U.A., Su M.S., Kuida K., Boucher D.M. Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. Proc. Natl. Acad. Sci. USA 2003, 100:12759-12764.
83. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., Locasale J.W., Son J., Zhang H., Coloff J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.
84. Young A., Lou D., McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2013, 3:112-123.
85. Zhang X.F., Settleman J., Kyriakis J.M., Takeuchi-Suzuki E., Elledge S.J., Marshall M.S., Bruder J.T., Rapp U.R., Avruch J. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 1993, 364:308-313.
86. Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., Hahn S.A., Triola G., Wittinghofer A., Bastiaens P.I., Waldmann H. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013, 497:638-642.